Christopher J. Senner

CIK: 0001648367

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (21.7%)

Position reduction

Option Exercises (M)2 (8.7%)

Derivative conversions

Awards (A)9 (39.1%)

Compensation grants

Other (G, F, J, C, D, …)7 (30.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

QNCX

Quince Therapeutics, Inc.

Director

EXEL

EXELIXIS, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (23 total)

QNCX
Quince Therapeutics, Inc.
Jun 11, 2026
Award(A)
Director Stock Option (Right to Buy)
Direct
2.7K shares-
EXEL
EXELIXIS, INC.
May 18, 2026
Sale(S)
Direct
34.9K shares at avg. $50.00$1.7M
EXEL
EXELIXIS, INC.
May 15, 2026
Tax Payment(F)
Direct
40.9K shares at avg. $51.10$2.1M
EXEL
EXELIXIS, INC.
Feb 26, 2026
Award(A)
Direct
52K shares-
EXEL
EXELIXIS, INC.
Feb 17, 2026
Sale(S)
Direct
30.6K shares at avg. $43.67$1.3M
EXEL
EXELIXIS, INC.
Feb 15, 2026
Tax Payment(F)
Direct
35.9K shares at avg. $43.92$1.6M
EXEL
EXELIXIS, INC.
Feb 13, 2026
Sale(S)
Direct
34.3K shares at avg. $43.00$1.5M
EXEL
EXELIXIS, INC.
Jan 15, 2026
Award(A)
Direct
149.5K shares-
EXEL
EXELIXIS, INC.
Jan 15, 2026
Tax Payment(F)
Direct
40.5K shares at avg. $45.23$1.8M
QNCX
Quince Therapeutics, Inc.
Jan 2, 2026
Award(A)
Director Stock Option (Right to Buy)
Direct
21.8K shares-
QNCX
Quince Therapeutics, Inc.
Jun 4, 2025
Award(A)
Director Stock Option (Right to Buy)
Direct
27K shares-
EXEL
EXELIXIS, INC.
May 16, 2025
Exercise(M)
Direct
100K shares at avg. $18.80$1.9M
EXEL
EXELIXIS, INC.
May 16, 2025
Sale(S)
Direct
100K shares at avg. $46.00$4.6M
EXEL
EXELIXIS, INC.
May 15, 2025
Tax Payment(F)
Direct
41.4K shares at avg. $44.65$1.8M
EXEL
EXELIXIS, INC.
Mar 31, 2025
Award(A)
Direct
170K shares-
EXEL
EXELIXIS, INC.
Feb 26, 2025
Award(A)
Direct
59.6K shares-
EXEL
EXELIXIS, INC.
Feb 24, 2025
Sale(S)
Direct
29.3K shares at avg. $36.14$1.1M
EXEL
EXELIXIS, INC.
Feb 24, 2025
Exercise(M)
Direct
29.3K shares at avg. $18.80$551K
EXEL
EXELIXIS, INC.
Feb 15, 2025
Tax Payment(F)
Direct
21.6K shares at avg. $35.00$756K
EXEL
EXELIXIS, INC.
Jan 16, 2025
Award(A)
Direct
133K shares-
EXEL
EXELIXIS, INC.
Jan 16, 2025
Tax Payment(F)
Direct
35.9K shares at avg. $37.27$1.3M
QNCX
Quince Therapeutics, Inc.
Jan 2, 2025
Award(A)
Director Stock Option (right to buy)
Direct
35.3K shares-
EXEL
EXELIXIS, INC.
Nov 15, 2024
Tax Payment(F)
Direct
17.5K shares at avg. $35.05$614K

		Type	Shares	Price		Ownership
Jun 11, 2026	QNCX Quince Therapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	2,700	-	-	Direct
May 18, 2026	EXEL EXELIXIS, INC.	Sale(S)	34,901	$50.00	$1,745,050	Direct
May 15, 2026	EXEL EXELIXIS, INC.	Tax Payment(F)	40,892	$51.10	$2,089,581	Direct
Feb 26, 2026	EXEL EXELIXIS, INC.	Award(A)	52,018	-	$0	Direct
Feb 17, 2026	EXEL EXELIXIS, INC.	Sale(S)	30,617	$43.67	$1,337,044	Direct
Feb 15, 2026	EXEL EXELIXIS, INC.	Tax Payment(F)	35,870	$43.92	$1,575,410	Direct
Feb 13, 2026	EXEL EXELIXIS, INC.	Sale(S)	34,278	$43.00	$1,473,954	Direct
Jan 15, 2026	EXEL EXELIXIS, INC.	Award(A)	149,474	-	$0	Direct
Jan 15, 2026	EXEL EXELIXIS, INC.	Tax Payment(F)	40,459	$45.23	$1,829,961	Direct
Jan 2, 2026	QNCX Quince Therapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	21,810	-	-	Direct
Jun 4, 2025	QNCX Quince Therapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	27,000	-	-	Direct
May 16, 2025	EXEL EXELIXIS, INC.	Exercise(M)	100,000	$18.80	$1,880,000	Direct
May 16, 2025	EXEL EXELIXIS, INC.	Sale(S)	100,000	$46.00	$4,600,000	Direct
May 15, 2025	EXEL EXELIXIS, INC.	Tax Payment(F)	41,422	$44.65	$1,849,492	Direct
Mar 31, 2025	EXEL EXELIXIS, INC.	Award(A)	170,009	-	-	Direct
Feb 26, 2025	EXEL EXELIXIS, INC.	Award(A)	59,648	-	-	Direct
Feb 24, 2025	EXEL EXELIXIS, INC.	Sale(S)	29,314	$36.14	$1,059,408	Direct
Feb 24, 2025	EXEL EXELIXIS, INC.	Exercise(M)	29,314	$18.80	$551,103	Direct
Feb 15, 2025	EXEL EXELIXIS, INC.	Tax Payment(F)	21,591	$35.00	$755,685	Direct
Jan 16, 2025	EXEL EXELIXIS, INC.	Award(A)	132,973	-	$0	Direct
Jan 16, 2025	EXEL EXELIXIS, INC.	Tax Payment(F)	35,949	$37.27	$1,339,819	Direct
Jan 2, 2025	QNCX Quince Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	35,274	-	-	Direct
Nov 15, 2024	EXEL EXELIXIS, INC.	Tax Payment(F)	17,506	$35.05	$613,585	Direct

1-23 of 23 transactions

About Senner Christopher J.

Senner Christopher J. (SEC CIK 0001648367) files insider reports with the SEC as Director of Quince Therapeutics, Inc. (QNCX) and EVP and CFO of EXELIXIS, INC. (EXEL).

Signal8 holds 15 ownership filings by Senner Christopher J., all Form 4s, filed between Nov 19, 2024 and Jun 15, 2026. Those filings report 23 transactions, from Nov 15, 2024 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Senner Christopher J.'s filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Senner Christopher J.

Jun 11, 2026: Grant or award of QNCX derivative securities (Form 4, code A).
May 18, 2026: Open-market sale of EXEL shares (Form 4, code S).
May 15, 2026: Tax withholding of EXEL shares (Form 4, code F).
Feb 26, 2026: Grant or award of EXEL shares (Form 4, code A).
Feb 17, 2026: Open-market sale of EXEL shares (Form 4, code S).

Other insiders filing for Quince Therapeutics, Inc. (QNCX)

Lamond David, Director
Roberts Brigette, Chief Corp. Affairs Officer
Thye Dirk, CEO and CMO
Ryan Charles S., President
Hannah Brendan, CBO, COO & CCO
McLoughlin Margaret, Director

How to read Form 4 transaction codes